TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mental Health E-screening in Pregnant and Postpartum Women
Brief Summary: To compare e-screening versus usual screening on: 1) women's and healthcare providers' views on feasibility and acceptability; 2) rates of detection of prenatal and postpartum depression and anxiety; 3) perceived risk and benefit of disclosure; 4) cost-effectiveness; 5) psychometric properties. We also aim to identify factors associated with feasibility of e-screening.Compared to usual screening:1) e-screening is as feasible; 2) e-screening yields similar rates of prenatal and postpartum depression and anxiety; 3) the mean score for risk of disclosure is significantly lower and benefit of disclosure is significantly higher in the e-screening group; 4) e-screening is as or more cost effective in detecting prenatal and postpartum depression and anxiety; 5) features of e-screening are significantly associated with feasibility and acceptability, whereas demographic factors are not; and 6) reliability and validity indices of ALPHA and EPDS are strongly correlated for both administration modes.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic Self-Report Assessment - Cancer (ESRA-C) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic Self-Report Assessment - Cancer (ESRA-C); Assigned to Arm(s): Intervention
B: Arm Label: Paper-based screening; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: E-screening; Type: EXPERIMENTAL; Interventions: Other: E-screening | Intervention Type: OTHER; Name: E-screening; Assigned to Arm(s): E-screening
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Check Your Drinking University version | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Check Your Drinking University version; Assigned to Arm(s): Intervention
D: Arm Label: MONARCA; Type: ACTIVE_COMPARATOR; Interventions: Device: MONARCA | Arm Label: NON-MONARCA; Type: PLACEBO_COMPARATOR; Interventions: Device: NON-MONARCA | Intervention Type: DEVICE; Name: MONARCA; Assigned to Arm(s): MONARCA | Intervention Type: DEVICE; Name: NON-MONARCA; Assigned to Arm(s): NON-MONARCA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label, 3 Crossover, Balanced Incomplete Block Study To Evaluate The Pharmacokinetics Of Umeclidinium Bromide and Vilanterol Trifenatate as Monotherapies and Concurrently in Healthy Chinese Subjects.
Brief Summary: This study is to assess the pharmacokinetics (PK), safety and tolerability of UMEC (62.5µg and 125µg) and VI (25µg) as monotherapies and combinations in healthy Chinese subjects.


Options:
A: Arm Label: UMEC/VI 125/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC/VI 125/25 mcg | Arm Label: UMEC/VI 62.5/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC/VI 62.5/25 mcg | Arm Label: UMEC 125 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC 125 mcg | Arm Label: UMEC 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC 62.5 mcg | Arm Label: VI 25 mcg; Type: EXPERIMENTAL; Interventions: Drug: VI 25 mcg | Intervention Type: DRUG; Name: UMEC/VI 125/25 mcg; Assigned to Arm(s): UMEC/VI 125/25 mcg | Intervention Type: DRUG; Name: UMEC/VI 62.5/25 mcg; Assigned to Arm(s): UMEC/VI 62.5/25 mcg | Intervention Type: DRUG; Name: UMEC 125 mcg; Assigned to Arm(s): UMEC 125 mcg | Intervention Type: DRUG; Name: UMEC 62.5 mcg; Assigned to Arm(s): UMEC 62.5 mcg | Intervention Type: DRUG; Name: VI 25 mcg; Assigned to Arm(s): VI 25 mcg
B: Arm Label: UMEC (62.5 mcg); Type: EXPERIMENTAL; Interventions: Drug: UMEC DPI, Drug: ICS/LABA medication, Drug: Albuterol/salbutamol Metered Dose Inhaler (MDI) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo DPI, Drug: ICS/LABA medication, Drug: Albuterol/salbutamol Metered Dose Inhaler (MDI) | Intervention Type: DRUG; Name: UMEC DPI; Assigned to Arm(s): UMEC (62.5 mcg) | Intervention Type: DRUG; Name: Placebo DPI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: ICS/LABA medication; Assigned to Arm(s): Placebo, UMEC (62.5 mcg) | Intervention Type: DRUG; Name: Albuterol/salbutamol Metered Dose Inhaler (MDI); Assigned to Arm(s): Placebo, UMEC (62.5 mcg)
C: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 125/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 125mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: GW642444 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo only | Intervention Type: DRUG; Name: GSK573719/GW642444 125/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: GSK573719 125mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GW642444 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo only; Assigned to Arm(s): Placebo
D: Arm Label: Umeclidinium/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 mcg | Intervention Type: DRUG; Name: Umeclidinium/Vilanterol 62.5/25 mcg; Assigned to Arm(s): Umeclidinium/Vilanterol | Intervention Type: DRUG; Name: Tiotropium 18 mcg; Assigned to Arm(s): Tiotropium

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a Fixed Combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects With COPD Who Continue To Have Symptoms on Tiotropium
Brief Summary: The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and continue to have symptoms while on tiotropium.


Options:
A: Arm Label: Umeclidinium/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 mcg | Intervention Type: DRUG; Name: Umeclidinium/Vilanterol 62.5/25 mcg; Assigned to Arm(s): Umeclidinium/Vilanterol | Intervention Type: DRUG; Name: Tiotropium 18 mcg; Assigned to Arm(s): Tiotropium
B: Arm Label: tiotropium + olodaterol high dose; Type: EXPERIMENTAL; Interventions: Drug: olodaterol, Drug: tiotropium | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol high dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol high dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium
C: Arm Label: QVA149 + placebo to tiotropium; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Arm Label: Tiotropium + placebo to QVA149; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Placebo to QVA149, Drug: Salbutamol/albuterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to QVA149, Drug: Placebo to tiotropium, Drug: Salbutamol/albuterol | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to QVA149; Assigned to Arm(s): Placebo, Tiotropium + placebo to QVA149 | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): Placebo, QVA149 + placebo to tiotropium, Tiotropium + placebo to QVA149
D: Arm Label: Olodaterol (BI1744) Low; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Olodaterol (BI 1744) High; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI 1744) High | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI1744) Low | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Isolated Strengthening and Functional Training on Strength, Running Mechanics, Postural Control and Injury Prevention in Novice Runners
Brief Summary: The purpose of this study is to understand the effects of muscle strengthening and balance exercise interventions on muscle strength, running mechanics and postural control in novice recreational runners. Participants will be assessed before and after they engage in an 8-week exercise intervention program.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: SHRED Osteoarthritis program | Arm Label: Control; Type: OTHER; Interventions: Other: SHRED Osteoarthritis program | Intervention Type: OTHER; Name: SHRED Osteoarthritis program; Assigned to Arm(s): Control, Intervention
B: Arm Label: Hard cushioned running shoes; Type: EXPERIMENTAL; Interventions: Other: Hard cushioned running shoes | Arm Label: Soft cushioned running shoes; Type: EXPERIMENTAL; Interventions: Other: Soft cushioned running shoes | Intervention Type: OTHER; Name: Hard cushioned running shoes; Assigned to Arm(s): Hard cushioned running shoes | Intervention Type: OTHER; Name: Soft cushioned running shoes; Assigned to Arm(s): Soft cushioned running shoes
C: Arm Label: Strengthening; Type: EXPERIMENTAL; Interventions: Other: Strengthening | Arm Label: Balance Training; Type: EXPERIMENTAL; Interventions: Other: Balance Training | Arm Label: Stretching; Type: EXPERIMENTAL; Interventions: Other: Stretching | Intervention Type: OTHER; Name: Strengthening; Assigned to Arm(s): Strengthening | Intervention Type: OTHER; Name: Balance Training; Assigned to Arm(s): Balance Training | Intervention Type: OTHER; Name: Stretching; Assigned to Arm(s): Stretching
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Experimental; Assigned to Arm(s): Experimental

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Health Worker Support to Help Patients Control Chronic Disease
Brief Summary: The purpose of this proposal is to compare the effectiveness of community health worker (CHW) support vs. usual primary care for helping chronically-ill, low-SES patients to improve control of chronic conditions. Upon enrollment each patient will select one of their multiple chronic conditions as a focus for the trial and work with his/her PCP to set a chronic disease management goal. Patients are then randomized to receive usual primary care vs. CHW support for moving towards that goal.


Options:
A: Arm Label: Telepharmacist intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Telepharmacist intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telepharmacist intervention; Assigned to Arm(s): Telepharmacist intervention
B: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
C: Arm Label: CHW Goal Support; Type: EXPERIMENTAL; Interventions: Behavioral: CHW Goal Support | Arm Label: Usual Primary Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHW Goal Support; Assigned to Arm(s): CHW Goal Support
D: Arm Label: 1; Type: OTHER; Interventions: Drug: Insulin glulisine, Drug: Insulin glargine, Drug: Metformin | Arm Label: 2; Type: OTHER; Interventions: Drug: Insulin glulisine, Drug: Insulin glargine, Drug: Metformin | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Health Worker Support to Help Patients Control Chronic Disease
Brief Summary: The purpose of this proposal is to compare the effectiveness of community health worker (CHW) support vs. usual primary care for helping chronically-ill, low-SES patients to improve control of chronic conditions. Upon enrollment each patient will select one of their multiple chronic conditions as a focus for the trial and work with his/her PCP to set a chronic disease management goal. Patients are then randomized to receive usual primary care vs. CHW support for moving towards that goal.


Options:
A: Arm Label: Guided Care; Type: EXPERIMENTAL; Interventions: Behavioral: Guided Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Guided Care; Assigned to Arm(s): Guided Care
B: Arm Label: G_AH; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care group | Arm Label: G_SP; Type: OTHER; Interventions: Other: Phone-based care group | Arm Label: G_NOMHAD; Type: EXPERIMENTAL; Interventions: Device: Platform NOMHADchronic | Intervention Type: DEVICE; Name: Platform NOMHADchronic; Assigned to Arm(s): G_NOMHAD | Intervention Type: OTHER; Name: Phone-based care group; Assigned to Arm(s): G_SP | Intervention Type: OTHER; Name: Usual care group; Assigned to Arm(s): G_AH
C: Arm Label: CHW Goal Support; Type: EXPERIMENTAL; Interventions: Behavioral: CHW Goal Support | Arm Label: Usual Primary Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHW Goal Support; Assigned to Arm(s): CHW Goal Support
D: Arm Label: Community-based nurse care management; Type: EXPERIMENTAL; Interventions: Other: Community-based nurse care management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Community-based nurse care management; Assigned to Arm(s): Community-based nurse care management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Brief Summary: This study will provide much needed information about how to optimize the quality of care and quality of life of Veterans who are survivors of prostate cancer.


Options:
A: Arm Label: IVR Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response Symptom Management, Behavioral: Tailored Newsletters | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response Symptom Management; Assigned to Arm(s): IVR Intervention | Intervention Type: BEHAVIORAL; Name: Tailored Newsletters; Assigned to Arm(s): IVR Intervention
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SCP care; Type: EXPERIMENTAL; Interventions: Other: SCP care | Intervention Type: OTHER; Name: SCP care; Assigned to Arm(s): SCP care
C: Arm Label: Survivorship Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Survivorship Intervention | Arm Label: Facing Forward; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Facing Forward | Intervention Type: BEHAVIORAL; Name: Survivorship Intervention; Assigned to Arm(s): Survivorship Intervention | Intervention Type: BEHAVIORAL; Name: Facing Forward; Assigned to Arm(s): Facing Forward
D: Arm Label: intervention group; Type: ACTIVE_COMPARATOR; Interventions: Device: distress thermometer | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: distress thermometer; Assigned to Arm(s): intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Niños Sanos, Familia Sana (Healthy Children/Healthy Family): A Multi-Intervention Program to Prevent Childhood Obesity in Mexican-Heritage Children in Rural California
Brief Summary: Obesity and overweight are health problems resulting from the interaction of predisposing genes with environmental, economic and social stimuli, in conjunction with excess caloric intake throughout growth from childhood to adulthood. Evidence suggests that a major barrier in controlling overweight/obesity is the complex interrelation of these factors, making single-approach interventions less likely to succeed than integrated, multi-faceted approaches. The proposed project aims to deliver a multi-faceted behavioral intervention developed over the past 18 months by a university-community /school-based collaborative. This project aims to provide new knowledge about the effectiveness of interventions designed specifically to achieve successful weight management among Mexican-origin children ages 3-8, and identify associated mediating factors. Deliverables will include community-based, collaborative and sustainable tools to support weight-management goals in this demographic. UC Davis and UC Cooperative Extension (UCCE) faculty form the investigator team, collaborating on key decision points with the project community in California's Central Valley. The investigators hypothesize that the identified mediating factors will increase fruit and vegetable consumption. The investigators also hypothesize an increase in the intensity and frequency of physical activity among children in the intervention group.


Options:
A: Arm Label: Arm 1; Type: OTHER; Interventions: Procedure: System level depression care quality improvement | Intervention Type: PROCEDURE; Name: System level depression care quality improvement; Assigned to Arm(s): Arm 1
B: Arm Label: Shared decision-making program; Type: EXPERIMENTAL; Interventions: Other: Shared decision-making program | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Shared decision-making program; Assigned to Arm(s): Shared decision-making program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care
C: Arm Label: Early implementation practices; Type: ACTIVE_COMPARATOR; Interventions: Other: Implementation of the MOHR assessment in primary care workflow | Arm Label: Delayed implementation practices; Type: OTHER; Interventions: Other: Implementation of the MOHR assessment in primary care workflow | Intervention Type: OTHER; Name: Implementation of the MOHR assessment in primary care workflow; Assigned to Arm(s): Delayed implementation practices, Early implementation practices
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Ninos Sanos Familia Sana | Arm Label: Comparison; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ninos Sanos Familia Sana | Intervention Type: BEHAVIORAL; Name: Ninos Sanos Familia Sana; Assigned to Arm(s): Comparison, Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Hospital-based Risk Reduction to Impede Vascular Events After Stroke
Brief Summary: The purpose of this study is to determine whether a culturally-sensitive multipronged post-discharge intervention can significantly reduce blood pressure, enhance achievement of guideline recommended targets for risk factor control, and lower recurrent vascular events in a low-income and middle-income (LMIC). The study will have 2 Phases - a qualitative phase (Phase 1) lasting less than one year involving development of the intervention through focus group methodologies and structured interviews, and a clinical trial phase (Phase 2)lasting 3 years involving a randomized trial testing the efficacy of the intervention.


Options:
A: Arm Label: Behavioral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: THRIVES | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: THRIVES; Assigned to Arm(s): Behavioral
B: Arm Label: Peer-Led Stroke Recurrence Prevention Education; Type: EXPERIMENTAL; Interventions: Behavioral: Prevent Return of Stroke | Arm Label: Usual Care (Delayed Intervention); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Prevent Return of Stroke | Intervention Type: BEHAVIORAL; Name: Prevent Return of Stroke; Assigned to Arm(s): Peer-Led Stroke Recurrence Prevention Education | Intervention Type: BEHAVIORAL; Name: Prevent Return of Stroke; Assigned to Arm(s): Usual Care (Delayed Intervention)
C: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Smart-phone based technology | Arm Label: Usual background care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smart-phone based technology; Assigned to Arm(s): Behavioral

Answer: A